SELECTA BIOSCIENCES INC (SELB) Stock Price, Quote, News and Overview
NASDAQ:SELB - Nasdaq - US8162121045 - Common Stock - Currency: USD
SELB Quote, Performance and Key Statistics
0.8812
-0.08 (-8%)
The current stock price of SELB is 0.8812 USD. In the past month the price decreased by -21.32%. In the past year, price decreased by -37.06%.
SELB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SELB
Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
Company Info
SELECTA BIOSCIENCES INC
65 Grove Street
Watertown MASSACHUSETTS 02472 US
CEO: Carsten Brunn
Employees: 58
Company Website: https://selectabio.com/
Phone: 16179231400.0
SELECTA BIOSCIENCES INC / SELB FAQ
What is the stock price of SELECTA BIOSCIENCES INC today?
The current stock price of SELB is 0.8812 USD. The price decreased by -8% in the last trading session.
What is the ticker symbol for SELECTA BIOSCIENCES INC stock?
The exchange symbol of SELECTA BIOSCIENCES INC is SELB and it is listed on the Nasdaq exchange.
On which exchange is SELB stock listed?
SELB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SELECTA BIOSCIENCES INC stock?
12 analysts have analysed SELB and the average price target is 3.57 USD. This implies a price increase of 305.13% is expected in the next year compared to the current price of 0.8812. Check the SELECTA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SELECTA BIOSCIENCES INC worth?
SELECTA BIOSCIENCES INC (SELB) has a market capitalization of 135.20M USD. This makes SELB a Micro Cap stock.
How many employees does SELECTA BIOSCIENCES INC have?
SELECTA BIOSCIENCES INC (SELB) currently has 58 employees.
What are the support and resistance levels for SELECTA BIOSCIENCES INC (SELB) stock?
SELECTA BIOSCIENCES INC (SELB) has a resistance level at 1.16. Check the full technical report for a detailed analysis of SELB support and resistance levels.
Is SELECTA BIOSCIENCES INC (SELB) expected to grow?
The Revenue of SELECTA BIOSCIENCES INC (SELB) is expected to decline by -72.53% in the next year. Check the estimates tab for more information on the SELB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SELECTA BIOSCIENCES INC (SELB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SELB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SELB, evaluating the profitability, health, valuation and growth aspects
- SELECTA BIOSCIENCES INC (SELB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SELECTA BIOSCIENCES INC (SELB) Sales and EPS estimates to see what analysts future expectations are.
- SELECTA BIOSCIENCES INC (SELB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SELECTA BIOSCIENCES INC (SELB) Insider and Institutional Ownership to learn about the owners and their transactions.
- SELECTA BIOSCIENCES INC (SELB) Stock Chart to make your own analysis
- SELECTA BIOSCIENCES INC (SELB) Latest news and press-releases to stay up to date.
Does SELECTA BIOSCIENCES INC (SELB) stock pay dividends?
SELB does not pay a dividend.
When does SELECTA BIOSCIENCES INC (SELB) report earnings?
SELECTA BIOSCIENCES INC (SELB) will report earnings on 2024-02-29, after the market close.
What is the Price/Earnings (PE) ratio of SELECTA BIOSCIENCES INC (SELB)?
SELECTA BIOSCIENCES INC (SELB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
SELB Technical Analysis
SELB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SELB. SELB may be in some trouble as it scores bad on both profitability and health.
SELB Financial Highlights
Over the last trailing twelve months SELB reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS decreased by -237.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.12% | ||
| ROE | -53.55% | ||
| Debt/Equity | 0.21 |
SELB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to SELB. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -228.11% and a revenue growth -72.53% for SELB